Methods for identifying improved, nonsedating alpha-2 agonists

Details for Australian Patent Application No. 2004279333 (hide)

Owner Allergan, Inc.

Inventors Gil, Daniel W.; Donello, John E.

Agent Davies Collison Cave

Pub. Number AU-A-2004279333

PCT Pub. Number WO2005/034849

Priority 10/891,740 15.07.04 US; 60/502,840 12.09.03 US

Filing date 19 August 2004

Wipo publication date 21 April 2005

International Classifications

A61K 31/4164 (2006.01) - 1,3-Diazoles

Event Publications

30 March 2006 PCT application entered the National Phase

  PCT publication WO2005/034849 Priority application(s): WO2005/034849

6 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004279336-Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions

2004279332-Nonsedating alpha-2 agonist 1- (2, 3-dimethyl-phenyl) -ethyl-1, 3-dihydro-imizadole-2-thione